HOME > ARCHIVE
ARCHIVE
- Focus on Pollinosis (2)
February 13, 2006
- JGPMA to Talk with JPMA About Job Sharing
February 13, 2006
- 2006 Pollen Websites
February 13, 2006
- Nationwide Delivery of Generics Is Possible: Mr Nakagawa
February 13, 2006
- New Prescription Form Taking Shape
February 13, 2006
- Japanese GE Market "a Big Opportunity": Dr Rummelt of Sandoz
February 13, 2006
- Pfizer Receives FDA Approval for New Anticancer Agent
February 13, 2006
- New Guidance Issued on On-site GCP Compliance Inspections
February 13, 2006
- Atypical Antipsychotic Abilify: Otsuka
February 6, 2006
- Proposed Revision of Medical Materials System Approved by Chuikyo
February 6, 2006
- Silodosin to Improve Dysuria: Kissei
February 6, 2006
- MEDICAL DEVICE NEWS IN BRIEF
February 6, 2006
- Femara for Breast Cancer: Novartis
February 6, 2006
- JSMI to Submit Petition on Self-medication to Korosho
February 6, 2006
- 3 Drugs, 1 Diagnostic Recommended for Approval
February 6, 2006
- Group of Pharmacy Chains Calls For Sale of Drugs via Internet
February 6, 2006
- Toyama, Nidek Granted Approval for Tosufloxacin Eye Drops
February 6, 2006
- Sysmex to Shift Focus to Disease Management
February 6, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 6, 2006
- Serono Japan Granted Approval for Follitropin a to Treat MHH
February 6, 2006
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
